Sanofi Pasteur Licenses Dengue Vaccine Technology from Maxygen

December 13, 2007
BioPharm International Editors

Maxygen, Inc. (Redwood City, CA), has announced the licensing of its proprietary dengue virus antigen technology to Sanofi Pasteur (Lyon, France).

Maxygen, Inc. (Redwood City, CA), has announced the licensing of its proprietary dengue virus antigen technology to Sanofi Pasteur (Lyon, France). Under the terms of the agreement, Maxygen will transfer to Sanofi Pasteur a portfolio of preclinical dengue antigens for development and worldwide commercialization of a second-generation vaccine. The deal could be worth up to $24.5 million for Maxygen. Sanofi Pasteur had recently presented positive results for their tetravalent dengue vaccine candidate after Phase 2 trials using Acambis technology.

The dengue virus is a mosquito-borne pathogen that infects over 50 million people each year, causing 500,000 hospitalizations, according to the World Health Organization.

Maxgen releaseSanofi Pasteur web site

Related Content:

News